 |
BioWorld-International-2011-08-24
KalVista Launches with $13.1M To Back DME Treatment R&D
GSK Spinout Autifony Brings in $16.4M for Hearing Loss Therapy
LONDON – The latest spin-out to emerge from GlaxoSmithKline (GSK) plc's restructuring has raised £10 million (US$16.4 million) from venture capital (VC) investors to fund the development of drug treatments for hearing loss and tinnitus. (BioWorld International)